--- title: "Clinical Trials In Adipose Stem Cells: A Clear 2026 Map" description: "The adipose stem cell clinical trials landscape in 2026: how many are registered, how few are recruiting, and what the phase mix really says." url: "https://savemyfat.com/adipose-clinical-trials-landscape-2026/" --- # Adipose-Derived Stem Cells: A Clinical Trials Landscape Overview #### Table of Contents - [Oscar Tellez](https://savemyfat.com/author/oscartellez/) - September 25, 2026 - 10:00 am ![Adipose tissue in a petri dish on a stainless base beside a monitor of trial data, the clinical trials landscape in miniature](https://savemyfat.com/wp-content/uploads/2026/08/adipose-clinical-trials-landscape-2026.png)Adipose-derived stem cells: a clinical trials landscape overview 2 Search the federal registry for adipose-derived stem cells and the list looks busy. Read the status column and a different picture appears. This guide maps the United States clinical trials landscape for adipose-derived cells: how many studies exist, how many are enrolling, how many stopped, and what a listing does and does not prove. **TLDR Roughly 170 to 195 registered studies with a United States location involve adipose-derived cells. Of the 169 records in the strict search, 75, about 44 percent, are withdrawn, terminated, suspended, or unknown, against 11 that are recruiting. Only 7 of the 169 are Phase 3. No adipose-derived product is FDA approved, and banking adipose tissue does not guarantee eligibility, access, or clinical benefit.** **Important Disclaimer:** Save My Fat does not provide FDA-approved treatments or cures for any disease, including the arthritis, neurologic, and other conditions named in this article. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently has FDA approval for any condition. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions. --- A registry entry is a filing, not a finding. A record describes what a sponsor intends to test, and it goes up before results exist. It says nothing about whether the intervention worked. That distinction carries weight here, because clinical trials are what advertising points to when it wants to sound scientific. The counts below come from one snapshot, taken on August 25, 2026. FDA’s roster of [approved cellular therapies](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products) lists no adipose-derived product for any disease. Save My Fat is a connector that links patients and providers with a United States tissue bank, and it does not collect, process, store, or treat tissue. What follows maps a research field, not a reason to expect anything from it. ## What the adipose stem cell clinical trials landscape looks like today It is small, overwhelmingly early stage, and marked by studies that stopped. Roughly 170 to 195 registered studies with a United States location involve adipose-derived cells or tissue. The range is honest rather than sloppy, because the number moves with the search. A strict query against the intervention field returns 169 United States records. A broader search that expands related concepts returns 196, and those extra records contain verified noise. Anyone publishing one precise number is hiding that judgment call. A [registry search](https://clinicaltrials.gov/search?term=adipose-derived%20stem%20cells) reproduces the picture, and none of those records represents an approved therapy. --- ## How many studies are active, completed, or stopped Most are not enrolling, and a large share ended early or went quiet. Of the 169 records in the strict United States query, 75, about 44 percent, are withdrawn, terminated, suspended, or unknown. Eleven are recruiting. Registry status Records out of 169 Withdrawn, terminated, suspended, or unknown 75, about 44 percent Recruiting 11 Hand-verified against the broader query, the recruiting count reaches 14, so roughly a dozen studies are open either way. The stopped or silent group is many times larger than the open one. A completed count is not in this snapshot, and this article will not estimate one. A long list of records is not a long list of ongoing science. --- ## Only 7 of the 169 records are Phase 3 Seven. That is the entire late stage picture in this snapshot. The rest are early phase studies, unphased device or procedure studies, or records with no phase listed. Phase Records Not applicable, device or procedure 44 Phase 1 37 Phase 2 28 No phase listed 25 Phase 1/2 21 Phase 3 7 Early Phase 1 5 Phase 2/3 1 Phase 4 1 Phase 3 matters because of what it demands. The federal [Phase 3 definition](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.21) describes expanded controlled and uncontrolled trials that gather the effectiveness and safety information needed to weigh overall benefit and risk, and it says such studies usually include from several hundred to several thousand subjects. Seven records at that stage describe a field still asking early questions rather than closing them. Readers who want the ladder in detail can review [what trial phases mean](https://savemyfat.com/what-clinical-trials-gov-phase-1-2-3-actually-mean/). --- ## Which conditions are studied most often Osteoarthritis dominates and nothing else is close. About 30 records pool knee, hip, and general osteoarthritis labels. Everything below sits in the low single digits. Condition label Records Osteoarthritis, knee, hip and general pooled about 30 Erectile dysfunction 7 Multiple sclerosis 6 COPD 5 Spinal cord injury 3 COVID-19 3 Alzheimer disease 3 Rheumatoid arthritis 3 Parkinson disease 3 Androgenetic alopecia 2 ALS 2 Diabetic foot ulcer 2 Traumatic brain injury 2 Critical limb ischemia 2 Read that table as a list of questions, not answers. A condition appears because a sponsor proposed studying it, and two or three records is a hypothesis, not evidence. FDA’s [consumer alert](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes) states that no regenerative medicine products are approved for COVID-19, orthopedic conditions, neurological disorders, cardiovascular or pulmonary disease, autism, blindness, or chronic pain. Anyone living with one of these conditions should take that fact to a licensed physician. --- ## Twelve verified trials, and what they actually show They show activity, not effectiveness. Each record below was pulled individually from the registry. The cell source column matters: autologous means a participant’s own cells, and allogeneic means cells from a donor. NCT number Condition Phase Status Enrollment Cell source Sponsor NCT04440189 Knee osteoarthritis Phase 3 Active, not recruiting 114 actual Autologous SVF GID BIO, Inc. NCT06121882 Knee osteoarthritis Phase 3 Active, not recruiting 173 actual Autologous Lipogems International spa NCT04368806 Knee osteoarthritis Phase 2/3 Active, not recruiting 173 actual Autologous AdMSC Nature Cell Co. Ltd. NCT03752827 Rotator cuff tear Not applicable, device pivotal Active, not recruiting 168 actual Autologous ADRC InGeneron, Inc. NCT05667649 Alzheimer disease Phase 1 Recruiting 18 estimated Autologous ADSC Regeneration Biomedical, Inc. NCT05951777 Traumatic brain injury Phase 2 Recruiting 51 estimated Autologous HB-adMSC Hope Biosciences LLC NCT06654193 Acute kidney injury Phase 1/2 Recruiting 70 estimated Allogeneic Hope Biosciences LLC NCT05789394 Recurrent glioblastoma Phase 1 Recruiting 20 estimated Allogeneic Mayo Clinic NCT03268603 ALS Phase 2 Active, not recruiting 75 actual Autologous Mayo Clinic NCT04520373 Spinal cord injury Phase 2 Active, not recruiting 40 estimated Autologous Mayo Clinic NCT03332238 Rotator cuff tear Phase 2 Active, not recruiting 56 estimated Autologous SVF Hospital for Special Surgery NCT03608579 Hip osteoarthritis Phase 1 Active, not recruiting 24 actual Autologous Mayo Clinic Autologous records outnumber allogeneic ones here, and the two allogeneic studies, in acute kidney injury and recurrent glioblastoma, are Phase 1/2 and Phase 1. One record, NCT04368806, an autologous AdMSC study in knee osteoarthritis, lists sites in South Korea as well as the United States. Nothing in the table is FDA approved. Only one of the twelve has posted results. NCT03268603, the autologous adipose-derived MSC study in ALS, posted results that are single-arm and open-label with no control group, so no efficacy conclusion can be drawn from them: 66 participants started and 57 completed. In that same single-arm, open-label record with no control group, 26 of 57 participants, 46 percent, had a serious adverse event, alongside 668 adverse events and 41 unexpected severe adverse events. The reported change in ALSFRS-R slope, minus 0.11 points per year, comes from that same uncontrolled single-arm, open-label design, which leaves nothing to compare it against. The record is not internally consistent either. Its protocol section lists enrollment of 75 actual while its results section says 66 started. The other eleven have posted no results. Recruiting is a staffing status, not a finding. The [trial record](https://clinicaltrials.gov/study/NCT05951777) for the autologous adipose-derived study in traumatic brain injury shows Phase 2 and recruiting, which together mean efficacy is still an open question. All of this work is investigational and early stage, and a licensed physician is the right person to read any record with a patient. --- ## Does an active listing mean a treatment is close to approval? No. A listing means a study was registered. FDA states on its [patient information page](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies) that the inclusion of a product in the registry database, or the fact that a firm has registered with FDA and listed its product, “does not mean the product is legally marketed.” The same page tells patients something blunter: “If you are being charged for these products or offered these products outside of a clinical trial, you are likely being deceived and offered a product illegally.” Completion is not approval either. ADIPOA-2 studied autologous adipose-derived stromal cells injected into the knee, ran as a Phase 2 at a university hospital in France, enrolled 100 participants, and completed in March 2024. It was a negative result. The [ADIPOA-2 record](https://clinicaltrials.gov/study/NCT02838069) carries no posted results, and the negative outcome sits in the publication. A finished trial can answer its question with a no. There is a regulatory reason these programs run as trials. FDA considers adipose a structural tissue, and the July 2020 [FDA guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal) states that isolating stromal vascular fraction is generally considered more than minimally manipulated. Under [21 CFR 1271.20](https://www.ecfr.gov/current/title-21/section-1271.20), a product failing those criteria is regulated as a drug, device, and/or biological product, which means an investigational new drug application to study it and approval before marketing. --- ## How to check any trial yourself Open the registry, find the record by its NCT number, and read three fields first: overall status, phase, and whether results are posted. Each registry record carries an NCT number, which is how you confirm a study exists. First, read the overall status. Recruiting means enrolling. Withdrawn, terminated, suspended, or unknown means the study is not running as planned. Second, read the phase. The [registry glossary](https://clinicaltrials.gov/study-basics/glossary) defines the labels, describing Early Phase 1 studies as exploratory work with “no therapeutic or diagnostic goals.” Third, check the results section. In this field, most records have nothing posted. Fourth, bring the record to a licensed physician before drawing any conclusion. A study nobody can point to by NCT number is a claim, not a study. --- ## What tissue banking does and does not do here Nothing in this landscape depends on banked tissue. Banking adipose tissue is preservation. It is not enrollment, not eligibility, and not a treatment, and it does not place anyone in the studies above. Trials set their own eligibility rules, and sponsors decide who enrolls. Any future use of preserved tissue would depend on FDA regulatory status, physician guidance, and whether approved or investigational pathways exist at that time. Readers who follow the enrolling end of the field can track [active adipose MSC trials](https://savemyfat.com/active-clinical-trials-in-adipose-derived-mscs-2026/), remembering that a change in status is a change in paperwork, not in proof. --- ## Frequently Asked Questions ### How many adipose stem cell trials are running in the United States? Roughly 170 to 195 registered studies with a United States location involve adipose-derived cells, depending on how the search is built. Only 11 of the 169 records in the strict search are recruiting. Registration is not evidence, and recruiting is not effectiveness. ### Why are so many records withdrawn or terminated? The registry does not explain each one, and this article will not guess. What the snapshot shows is scale: 75 of 169 United States records, about 44 percent, are withdrawn, terminated, suspended, or unknown, against 11 recruiting. ### What is the difference between autologous and allogeneic studies? Autologous studies use a participant’s own cells. Allogeneic studies use cells from a donor. Both appear among the twelve records above, both are investigational, and neither has produced an FDA-approved adipose-derived product. ### Can banking adipose tissue get me into a clinical trial? No. Banking is preservation, and it does not connect a patient to any treatment pathway or study. Sponsors set eligibility, and any future use depends on FDA regulatory status, physician guidance, and the pathways available at that time. --- ## Key Takeaways The adipose trial landscape is smaller and more fragile than a search result suggests. Roughly 170 to 195 registered studies with a United States location involve adipose-derived cells, and of the 169 records in the strict search, 75, about 44 percent, are withdrawn, terminated, suspended, or unknown, against 11 recruiting. Only 7 are Phase 3. Of the twelve verified trials named here, one has posted results, and those are single-arm and open-label with no control group. No adipose-derived product is FDA approved. Registration is not evidence, recruiting is not effectiveness, and banking does not guarantee eligibility, access, or clinical benefit. Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time. Readers weighing adipose tissue banking for potential future use can review [current pricing](https://savemyfat.com/pricing/) or begin a conversation through the [contact page](https://savemyfat.com/contact-us/). --- *Save My Fat partners with L2 Bio for laboratory processing and storage.* *This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about adipose tissue banking or research participation.* **About the author:** Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice. **Related guide:** [adipose stem cell trials](https://savemyfat.com/adipose-stem-cell-clinical-trials/). Follow Save My Fat on Google Set us as a preferred source and Google will show our latest updates more often in your results. [PrevPreviousAdipose Stem Cell Hair Restoration: What the Research Actually Shows](https://savemyfat.com/adipose-cell-therapy-hair-restoration-research/) [NextPhase 1 Trial Services: What They Are and Who Provides ThemNext](https://savemyfat.com/phase-1-clinical-trial-services/) Clinical Trials ### [Phase 1 Trial Services: What They Are and Who Provides Them](https://savemyfat.com/phase-1-clinical-trial-services/) [Read More »](https://savemyfat.com/phase-1-clinical-trial-services/) Oscar Tellez 09/26/2026 10:00 AM [![Adipose tissue in a petri dish on a stainless base beside a monitor of trial data, the clinical trials landscape in miniature](https://savemyfat.com/wp-content/uploads/2026/08/adipose-clinical-trials-landscape-2026-768x768.png)](https://savemyfat.com/adipose-clinical-trials-landscape-2026/) Clinical Trials ### [Adipose-Derived Stem Cells: A Clinical Trials Landscape Overview](https://savemyfat.com/adipose-clinical-trials-landscape-2026/) [Read More »](https://savemyfat.com/adipose-clinical-trials-landscape-2026/) Oscar Tellez 09/25/2026 10:00 AM [![Lock of dark hair, a vial and a packaged syringe on a lab bench below a hair follicle cross section, cell therapy under study](https://savemyfat.com/wp-content/uploads/2026/08/adipose-cell-therapy-hair-restoration-research-768x768.png)](https://savemyfat.com/adipose-cell-therapy-hair-restoration-research/) Clinical Trials ### [Adipose Stem Cell Hair Restoration: What the Research Actually Shows](https://savemyfat.com/adipose-cell-therapy-hair-restoration-research/) [Read More »](https://savemyfat.com/adipose-cell-therapy-hair-restoration-research/) Oscar Tellez 09/24/2026 10:00 AM Clinical Trials ### [The Process for an Expanded Access Program Request, Step by Step](https://savemyfat.com/expanded-access-program-request-process/) [Read More »](https://savemyfat.com/expanded-access-program-request-process/) Oscar Tellez 09/23/2026 10:00 AM Clinical Trials ### [Expanded Access Program Services: What They Cover and What They Don’t](https://savemyfat.com/expanded-access-program-services/) [Read More »](https://savemyfat.com/expanded-access-program-services/) Oscar Tellez 09/22/2026 10:00 AM Adipose Banking ### [Autologous vs Allogeneic: What the Difference Means for Banked Tissue](https://savemyfat.com/adipose-banking-autologous-vs-allogeneic/) [Read More »](https://savemyfat.com/adipose-banking-autologous-vs-allogeneic/) Oscar Tellez 09/21/2026 10:00 AM ```json [{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/savemyfat.com\/adipose-clinical-trials-landscape-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https:\/\/savemyfat.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https:\/\/savemyfat.com\/our-blog\/","name":"Our Blog"}},{"@type":"ListItem","position":"3","item":{"@id":"https:\/\/savemyfat.com\/category\/clinical-trials\/","name":"Clinical Trials"}},{"@type":"ListItem","position":"4","item":{"@id":"https:\/\/savemyfat.com\/adipose-clinical-trials-landscape-2026\/","name":"Adipose-Derived Stem Cells: A Clinical Trials Landscape Overview"}}]}]},{"@context":"https:\/\/schema.org","@graph":[{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","description":"Oscar Tellez is the Founder of SaveMyFat, a company that connects patients and physicians with a U.S. tissue bank for adipose tissue banking, so a person's own tissue can be preserved for potential future use in FDA-regulated pathways. He is not a physician.","url":"https:\/\/savemyfat.com\/oscar-tellez","email":"info@savemyfat.com","image":{"@type":"ImageObject","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/05\/Oscar-Headshot-Rounded-1.png","width":"200","height":"200"},"worksFor":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"knowsAbout":["Adipose Tissue Banking","Cryopreservation","Regenerative Medicine Regulation","Adipose-Derived Cells","Expanded Access Pathways"],"sameAs":["https:\/\/savemyfat.com\/oscar-tellez","https:\/\/www.linkedin.com\/in\/o-tellez\/","https:\/\/www.facebook.com\/savemyfat\/","https:\/\/www.instagram.com\/savemyfat\/"]},{"@type":"Article","@id":"https:\/\/savemyfat.com\/adipose-clinical-trials-landscape-2026\/#article","headline":"Adipose-Derived Stem Cells: A Clinical Trials Landscape Overview","url":"https:\/\/savemyfat.com\/adipose-clinical-trials-landscape-2026\/","mainEntityOfPage":{"@type":"WebPage","@id":"https:\/\/savemyfat.com\/adipose-clinical-trials-landscape-2026\/"},"datePublished":"2026-09-25T10:00:00-04:00","dateModified":"2026-08-26T17:23:25-04:00","description":"The adipose stem cell clinical trials landscape in 2026: how many are registered, how few are recruiting, and what the phase mix really says.","inLanguage":"en-US","articleSection":"Adipose Tissue Banking","author":{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","url":"https:\/\/savemyfat.com\/oscar-tellez"},"publisher":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"image":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/08\/adipose-clinical-trials-landscape-2026.png"}]},{"@context":"https:\/\/schema.org","@type":"WebPage","@id":"https:\/\/savemyfat.com\/adipose-clinical-trials-landscape-2026\/#webpage","url":"https:\/\/savemyfat.com\/adipose-clinical-trials-landscape-2026\/","name":"Clinical Trials in Adipose Stem Cells: A Clear 2026 Map","speakable":{"@type":"SpeakableSpecification","cssSelector":[".smf-speakable"]}}] ```